Problems arising in antimicrobial therapy due to false susceptibility testing

Journal of Chemotherapy

Volumn 9, Issue SUPPL. 1, 1997, Pages 25-35

  Cunha, B A ^a,b  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

Sensitivity testing; Susceptibility testing

Indexed keywords

AMINOGLYCOSIDE; AMOXICILLIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZTREONAM; CEFALEXIN; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLINDAMYCIN; DOXYCYCLINE; ERYTHROMYCIN; GENTAMICIN; MACROLIDE; METHENAMINE MANDELATE; METRONIDAZOLE; NAFCILLIN; NALIDIXIC ACID; NETILMICIN; NITROFURANTOIN; OFLOXACIN; OXOLINIC ACID; PENICILLIN DERIVATIVE; POLYMYXIN; POLYMYXIN B; QUINOLONE DERIVATIVE; SULTAMICILLIN; TETRACYCLINE; TETRACYCLINE DERIVATIVE; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; BILE; BODY FLUID; CONFERENCE PAPER; ERROR; HUMAN; INFECTION; LABORATORY TEST; MINIMUM INHIBITORY CONCENTRATION; PHARMACOKINETICS; PRACTICE GUIDELINE; SERUM; URINE;

HUMANS; MICROBIAL SENSITIVITY TESTS; REPRODUCIBILITY OF RESULTS;

EID: 0030744461     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (15)

1. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibilty testing: 4th informational supplement. M100-S4. NCCLS, Villanova, PA, 1992.
2. York MK. Reporting susceptibility test results - are we really communicating with physicians? Clin Microbiol Newslett 1996; 18: 177-182.
3. Doern GV, Vautour R, Gaudet M, Levy B. Clinical impact of rapid in vitro susceptibility testing and bacterial identification. J Clin Microbiol 1994; 32: 1757-1762.
4. Brodowy BA, Guglielmo BJ, York MK, Herfindal ET, Brooks GF. Experience with selective reporting of susceptibility to antimicrobial agents. Am J Hosp Pharm 1989; 46: 1816-1818.
5. Biedenbach DJ, Jones RN. Interpretive errors using an automated system for the susceptibility testing of imipenem and aztreonam. Diagn Microbiol Infect Dis 1995; 21: 57-60.
6. Marshall SA, and the Axtreonam Study Group. Serious interpretive error among three commercial systems for susceptibility testing of aztreonam. Diagn Microbiol Infect Dis 1995; 22: 249-251.
7. Cunha BA, Ortega AM. Antibiotic failure. Med Clin North Am 1995; 79: 663-672.
8. Edmond MB, Wenzel RP, Pasculle AW. Vancomycin-resistant Staphylococcus aureus: perspective on measures needed for control. Ann Intern Med 1996; 124: 329-334.
9. Cunha BA, Comer JB. Pharmacokinetic considerations in the treatment of urinary tract infections. Connecticut Med 1979; 43:347-353.
10. Nicolle LE. Measurement and signficance of antibiotic activity in the urine. In: Lorian V (ed). Antibiotics in Laboratory Medicine, ed. 4. Baltimore, Williams & Wilkins, 1996: 793-812.
11. Johnson CC. In vitro testing: correlations of bacterial susceptibility, body fluid levels, and effectiveness of antibacterial therapy. In: Lorian V (ed). Antibiotics in Laboratory Medicine, ed. 4. Baltimore, Williams & Wilkins, 1996: 813-834.
12. Stamey TA, Fair WR, Timothy MM. Serum versus urinary antimicrobial concentration in cure of urinary tract infections. N Engl J Med 1974; 291: 1159-1163.
13. Shea KW, Cunha BA. Doxycycline activity against Streptococcus pneumoniae. Chest 1995; 108: 1175-1176.
14. Lorian V, Sabath LD. Effect of pH on the activity of erythromycin against 500 isolates of gram-negative bacilli. Applied Microbiol 1970; 20: 754-756.
15. Absalon J, Domenico P, Ortega AM, Cunha BA, Qadri SMH. The antibacterial activity of ofloxacin versus ciprofloxacin against Pseudomonas aeruginosa in human urine. Adv Ther 1996; 13: 29-37.